ACRSAclaris Therapeutics, Inc.

$407M

Q4 2018 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$4M+267.3% YoY

Gross Profit

$160,0004.4% margin

Operating Income

-$39M-1064.0% margin

Net Income

-$39M-1050.7% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

+125.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$276M

Total Liabilities

$60M

Stockholders' Equity

$215M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$999,000	+267.3%
Gross Profit	$160,000	$245,000	-34.7%
Operating Income	-$39M	-$25M	-53.4%
Net Income	-$39M	-$23M	-68.1%

Revenue Segments

Product

$2M52%

Laboratory Research Revenue

$1M35%

Other Revenue

$500,00014%

ACRS Q4 2018 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena